Last updated: July 30, 2026
TRAVASOL 2.75% sulfite-free w/ electrolytes in dextrose 20% is an IV parenteral nutrition (PN) amino acid with carbohydrate formulation. Public, drug-level revenue and utilization data are not provided in the available record, and no FDA approval-year, label, discontinued/active status, or audited financial history by product/SKU is available here.
No complete, accurate market-dynamics and financial-trajectory assessment can be produced without reliable source-grade inputs (FDA product status and Orange Book status, launch/discontinuation dates, wholesaler or claims volumes, payer or hospital formulary penetration, and audited manufacturer revenue tied to this exact NDC and container configuration).
What market dynamics drive TRAVASOL 2.75% sulfite-free PN dextrose 20% plastic-container sales?
Answer (what drives demand): Demand is driven by hospital PN utilization, neonatal/critical care volume, PN compounding avoidance, supply reliability, and contract pricing dynamics for IV nutrition kits and amino acid/dextrose solutions.
Key demand drivers
- Clinical setting dependence: PN use concentrates in ICUs, neonatal units, oncology infusion, and perioperative care where enteral tolerance is limited.
- Formulation preference constraints: Clinicians and pharmacy buyers select based on stability, container compatibility, electrolyte content, and excipient tolerability (here, “sulfite-free”).
- Supply and continuity: PN lines experience capacity disruptions and substitution decisions; product continuity can matter more than brand marketing.
- Procurement structure: Hospital systems buy through GPOs, IDNs, and tender contracts that compress branded pricing and shift volume quickly to “contract winners.”
Key price and margin drivers
- GPO contracting and AMP pressure: PN drugs are often priced via competitive tenders; margins depend on awarded contract tiers.
- Substitution pressure: Comparable amino acid/dextrose PN solutions can displace volume if available and contract-preferred.
- Freight and handling: Plastic container logistics can affect distribution cost, but most pricing impact is driven by contract terms and allocation behavior during shortages.
What is the competitive landscape for TRAVASOL sulfite-free PN with dextrose 20%?
Answer (who competes): The competitive set is other IV amino acid solutions with dextrose and electrolytes used for PN, including both branded and authorized generics, and compounded alternatives used by hospital pharmacies.
Competitive clusters
- Commercial PN solutions (amino acids + dextrose + electrolytes; different concentrations and osmolarities).
- Private-label and authorized generic PN supplied under contract.
- Compounding substitution: Some hospitals compound amino acid and carbohydrate components to meet patient-specific electrolyte/osmolality needs.
Differentiation vectors buyers apply
- Sulfite-free excipient profile for patients with sensitivity concerns.
- Electrolyte package alignment with institutional PN protocols.
- Concentration and container format that fit nursing workflow and compounding constraints.
How does exclusivity and patent/IP risk affect TRAVASOL’s pricing power?
Answer: Branded PN products generally face earlier generic/authorized-generic substitution pressures. Without Orange Book and patent listings for this exact product/NDC, the patent/IP risk profile cannot be mapped accurately.
What to check for a product like this (for defensibility timelines)
- Orange Book listed patents for formulation, use, or manufacturing.
- Patent expiration windows and any re-listed patents.
- Section viii carve-outs and any manufacturing-change patents.
- Paragraph IV filings (if any) tied to the exact NDC strength/container.
What is the Orange Book status of TRAVASOL 2.75% sulfite-free w/ electrolytes in dextrose 20% in plastic container?
Answer: Not available in the provided record; no reliable Orange Book status can be stated.
When does TRAVASOL lose exclusivity or face generic entry risk?
Answer: Not determinable from the provided record. A correct timeline requires FDA exclusivity and Orange Book patent expiration dates for the specific NDC and presentation.
What FDA pathway and regulatory status governs TRAVASOL PN supply and switching?
Answer: Not available in the provided record. A correct regulatory profile requires FDA labeling and approval pathway specifics for this product presentation.
Switching impact factors
- Label restrictions and indications for PN populations.
- Stability and compatibility constraints (affects compounding substitution).
- Shortage designations or supply interruptions that trigger temporary substitution.
How strong is the commercial trajectory of TRAVASOL based on market access and hospital contracting?
Answer: Not available in the provided record. A financial trajectory requires (1) historical units and (2) net revenue by product/SKU and (3) contract pricing history.
Hospital procurement mechanics that typically shape PN brand performance
- Contract wins drive durable volume; losing a contract can cause rapid share loss.
- Formulary committees update PN protocols on a multi-quarter cycle.
- System-level standardization favors fewer SKUs across facilities.
What are the most likely revenue and volume drivers for TRAVASOL in the near to mid term?
Answer: Near-term performance is likely driven by PN volume and supply reliability, while mid-term is driven by substitution and contract pricing outcomes.
Near-term drivers
- PN utilization at hospitals (ICU census, surgery volumes, neonatal admissions).
- Shortage/availability environment that influences whether pharmacies default to TRAVASOL versus substitutes.
Mid-term drivers
- Authorized generic and alternative PN solution pricing under contract.
- Evidence of tolerability or formulary adoption for sulfite-free selection.
What manufacturing and supply-chain factors impact TRAVASOL availability and financial results?
Answer: PN product financial outcomes track manufacturing uptime, container line throughput, QA release cycle times, and allocation management.
Supply-chain vectors
- Batch release lead time affecting order fulfillment and backorders.
- Container sourcing and line capacity for plastic units.
- Quality system deviations that can trigger distribution holds.
What generic launch scenarios could affect TRAVASOL’s sales and margins?
Answer: Not determinable from the provided record. A scenario requires confirmed generic/authorized generic entrants, Paragraph IV status, and Orange Book expiration.
Generic scenario mechanics (typical in PN markets)
- Tender-price undercut after authorized generic arrival.
- Formulary substitution once supply is stable.
- Volume migration to lowest-cost contract SKU compatible with PN protocols.
Key Takeaways
- TRAVASOL 2.75% sulfite-free PN dextrose 20% plastic-container demand is primarily a function of hospital PN utilization, formulary adoption, and supply reliability.
- Competitive pressure in PN is typically contract-driven and can shift volume quickly after alternative PN solutions gain favored status.
- A defensible exclusivity, generic entry, and financial trajectory analysis cannot be completed from the information provided because FDA status, patent/Orange Book data, and audited revenue or unit history are not present in the record.
FAQs
- What data series best predict hospital demand for amino acid/dextrose PN solutions like TRAVASOL?
- How do sulfite-free excipient requirements influence formulary selection in neonatal and ICU PN workflows?
- What contract structures (GPO/IDN tenders) most often determine net price for IV PN products?
- How does plastic container availability change substitution decisions during PN supply disruptions?
- What regulatory signals (labeling changes, manufacturing holds, shortages) typically precede volume swings in PN brands?
References
- Not available from the provided record.
